154 related articles for article (PubMed ID: 34602349)
1. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Culine S; Harter V; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Abadie-Lacourtoisie S; Geoffrois L; Fiore FD; Roubaud G; Barthélémy P; Voog E; Emambux S; Serrate C; Saldana C; Nguyen-Tan-Hon T; Loriot Y; Eymard JC; Huillard O; Rolland F; Houédé N; Spano JP; Demery ME; Vieillot S; L'Haridon T; Hilgers W; Allory Y; Pfister C;
Clin Genitourin Cancer; 2021 Dec; 19(6):554-562. PubMed ID: 34602349
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
3. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Pfister C; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulié M; Allory Y; Harter V; Culine S;
J Clin Oncol; 2022 Jun; 40(18):2013-2022. PubMed ID: 35254888
[TBL] [Abstract][Full Text] [Related]
4. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C; Gravis G; Flechon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulie M; Allory Y; Harter V; Culine S;
Lancet Oncol; 2024 Feb; 25(2):255-264. PubMed ID: 38142702
[TBL] [Abstract][Full Text] [Related]
5. Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities.
Ruplin AT; Spengler AMZ; Montgomery RB; Wright JL
Clin Genitourin Cancer; 2020 Oct; 18(5):e557-e562. PubMed ID: 32201105
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
van de Putte EE; Mertens LS; Meijer RP; van der Heijden MS; Bex A; van der Poel HG; Kerst JM; Bergman AM; Horenblas S; van Rhijn BW
World J Urol; 2016 Feb; 34(2):157-62. PubMed ID: 26184106
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience.
Lemiński A; Kaczmarek K; Byrski T; Słojewski M
PLoS One; 2021; 16(11):e0259526. PubMed ID: 34731219
[TBL] [Abstract][Full Text] [Related]
9. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
[TBL] [Abstract][Full Text] [Related]
10. Comment on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: Results of the GETUG-AFU V05 VESPER trial.
Ye JJ; Ren SQ; Bao YG
Asian J Surg; 2023 Feb; 46(2):1163-1164. PubMed ID: 36088195
[No Abstract] [Full Text] [Related]
11. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
Ravi P; Pond GR; Diamantopoulos LN; Su C; Alva A; Jain RK; Skelton WP; Gupta S; Tward JD; Olson KM; Singh P; Grunewald CM; Niegisch G; Lee JL; Gallina A; Bandini M; Necchi A; Mossanen M; McGregor BA; Curran C; Grivas P; Sonpavde GP
BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
[TBL] [Abstract][Full Text] [Related]
12. An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
Montazeri K; Dranitsaris G; Thomas JD; Curran C; Preston MA; Steele GS; Kilbridge KL; Mantia C; Ravi P; McGregor BA; Mossanen M; Sonpavde G
Urol Oncol; 2021 Dec; 39(12):834.e1-834.e7. PubMed ID: 34162500
[TBL] [Abstract][Full Text] [Related]
13. Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Culine S; Harter V; Krucker C; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Fontugne J; Allory Y; Pfister C;
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980628
[TBL] [Abstract][Full Text] [Related]
14. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
[TBL] [Abstract][Full Text] [Related]
15. Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data.
Joyce DD; Wymer KM; Sharma V; Moriarty JP; Borah BJ; Geynisman DM; Plimack ER; Costello BA; Pagliaro LC; Boorjian SA
Cancer; 2022 Dec; 128(24):4194-4202. PubMed ID: 36251574
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
[TBL] [Abstract][Full Text] [Related]
17. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
Matsubara N; Mukai H; Naito Y; Nezu M; Itoh K
Asia Pac J Clin Oncol; 2013 Dec; 9(4):310-7. PubMed ID: 23127231
[TBL] [Abstract][Full Text] [Related]
18. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.
Pfister C; Harter V; Allory Y; Radvanyi F; Culine S;
Contemp Clin Trials Commun; 2020 Mar; 17():100536. PubMed ID: 32083220
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy.
Hemenway G; Lewis B; Ghatalia P; Anari F; Plimack ER; Kokate R; Handorf E; Deng M; Geynisman DM; Zibelman M
Eur Urol Oncol; 2023 Aug; 6(4):431-436. PubMed ID: 35792045
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.
Yin M; Joshi M; Meijer RP; Glantz M; Holder S; Harvey HA; Kaag M; Fransen van de Putte EE; Horenblas S; Drabick JJ
Oncologist; 2016 Jun; 21(6):708-15. PubMed ID: 27053504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
